€28.91
0.22% day before yesterday
Xetra, Sep 06, 05:37 pm CET
ISIN
DE000BAY0017
Symbol
BAYN
Sector
Industry

Bayer Stock price

€28.91
+3.60 14.20% 1M
+2.27 8.50% 6M
-4.72 14.04% YTD
-21.21 42.32% 1Y
-18.84 39.45% 3Y
-38.08 56.84% 5Y
-76.69 72.62% 10Y
Xetra, Closing price Fri, Sep 06 2024
-0.07 0.22%
ISIN
DE000BAY0017
Symbol
BAYN
Sector
Industry

Key metrics

Market capitalization €28.40b
Enterprise Value €71.25b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 15.72
EV/Sales (TTM) EV/Sales 1.51
P/S ratio (TTM) P/S ratio 0.60
P/B ratio (TTM) P/B ratio 0.80
Dividend yield 0.38%
Last dividend (FY23) €0.11
Revenue growth (TTM) Revenue growth -3.29%
Revenue (TTM) Revenue €47.11b
EBIT (operating result TTM) EBIT €7.62b
Free Cash Flow (TTM) Free Cash Flow €4.53b
Cash position €3.89b
EPS (TTM) EPS €-1.29
P/E forward 11.89
P/S forward 0.61
EV/Sales forward 1.52
Show more

Create a Free Account to create an Bayer alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Bayer Stock Analysis

Analyst Opinions

18 Analysts have issued a Bayer forecast:

3x Buy
17%
15x Hold
83%

Analyst Opinions

18 Analysts have issued a Bayer forecast:

Buy
17%
Hold
83%

Financial data from Bayer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
47,113 47,113
3% 3%
100%
- Direct Costs 19,755 19,755
1% 1%
42%
27,358 27,358
6% 6%
58%
- Selling and Administrative Expenses 10,111 10,111
13% 13%
21%
- Research and Development Expense 5,497 5,497
8% 8%
12%
11,750 11,750
1% 1%
25%
- Depreciation and Amortization 4,131 4,131
7% 7%
9%
EBIT (Operating Income) EBIT 7,619 7,619
2% 2%
16%
Net Profit -1,266 -1,266
187% 187%
-3%

In millions EUR.

Don't miss a Thing! We will send you all news about Bayer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bayer Stock News

Neutral
Seeking Alpha
about 18 hours ago
Bayer's Q2 2024 results were mixed, with strong Pharmaceuticals performance offsetting challenges in Crop Science and stable Consumer Health results. The reaffirmation of full-year guidance and a significant legal win in the "Schaffner vs. Monsanto" case offer some reassurance to investors. Under all the litigation noise, Bayer is still a strong, innovative business, with potential in both agri...
AD HOC NEWS
2 days ago
Die Bodenbildung der Aktien von Bayer DE000BAY0017 nimmt auch im schwächelnden Gesamtmarkt am Freitag weiter Form an.
Neutral
Business Wire
2 days ago
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new oncology data, including a late-breaking, comprehensive analysis from the Phase III ARANOTE trial investigating NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain,...
More Bayer News

Company Profile

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Head office Germany
CEO William Anderson
Employees 99,723
Founded 1863
Website www.bayer.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today